The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor

Becq, Frédéric; Mirval, Sandra; Carrez, Thomas; Lévêque, Manuella; Billet, Arnaud; Coraux, Christelle; Sage, Édouard; Cantereau, Anne

doi:10.1183/13993003.00671-2021

Public

The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor

Published in European Respiratory Journal • Jul 15, 2021

Authors:

Frédéric Becq

Sandra Mirval

Thomas Carrez

Abstract

Trikafta, currently the leading therapeutic in cystic fibrosis (CF), has demonstrated a real clinical benefit. This treatment is the triple combination therapy of two folding correctors elexacaftor/tezacaftor (VX445/VX661) plus the gating potentiator ivacaftor (VX770). In this study, our aim was to ...

Subject

Ivacaftor

Cystic fibrosis

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!